It's Apples Versus Oranges in the PI3 Kinase Race
In addition to camptothecins and HDAC inhibitors, Arno Therapeutics Inc.'s Also see "Arno Therapeutics" - Scrip, 1 October,...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "It’s Apples vs. Oranges in the PI3 Kinase Race," features profiles of Arno Therapeutics, Intellikine and Paloma Pharmaceuticals. Plus these Start-Ups Across Health Care: Mesynthes, Miracor Medical Systems, Silicos, Vantia and Vexim.
It's Apples Versus Oranges in the PI3 Kinase Race
In addition to camptothecins and HDAC inhibitors, Arno Therapeutics Inc.'s Also see "Arno Therapeutics" - Scrip, 1 October,...
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.